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with knee OA at baseline and incident OA as a minimum of one
point increase in total JSN score in patients with no knee OA at
baseline.
Odds ratios were calculated by logistic regression, adjusted for
age, sex, body mass index and family effect. The odds ratios
were transformed to risk ratios.
Results: Of the 208 patients (104 sibling pairs) 193 patients com-
pleted the follow-up of two years. The analysis was performed in
a total of 154 patients for whom UCTX-II levels at baseline were
available and who were either male or postmenopausal female
without hormone replacement therapy. The average age was 61
years, and 75% were female. The median (range) UCTX-II level
was 243 (44 - 786) ng/mmol creatine for all patients with cut-off
points for the middle and high tertile 199 and 306 ng/mmol crea-
tine respectively. In the whole group, 31 patients had an increase
in JSN score, 25 with progression of knee OA and 6 with incident
knee OA.
77 patients (50%) had knee OA at baseline of whom 25 patients
(33%) progressed. The median (range) UCTX-II level was 208
(61 - 700) ng/mmol creatine for patients without progression of
OA in the knee and 281 (113-660) for patients with progression
of OA in the knee. The median difference was 73 (95% C.I. 11.4
- 134.6) ng/mmol creatine. The adjusted risk ratio for developing
radiographic progression in the knee was 5.2 (95% C.I. 3.0 -
6.0) for the middle tertile and 4.5 (95% C.I. 1.7 - 5.9) for the
upper tertile of the baseline distribution of UCTX-II. Analysis for
patients with progression and incident knee OA combined gave
the same results.
Conclusions: Patients with an increased UCTX-II level at base-
line have an elevated risk to develop radiographic progression of
knee OA after two years. However, the range of UCTX-II levels
in patients without progression is even wider than the range
of UCTX-II in patients with progression. Thus, UCTX-II levels
at an individual level cannot predict which patients will show
progression in knees with OA in two years.
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Purpose: The extend of OA within each joint is usually assessed
by radiographic characteristics and expressed as the Kellgren
score. Radiographs are, however, poorly sensitive for monitoring
and assessing (the progression of) the disease. Biochemical
markers have been identified for bone, cartilage and synovium
turnover in humans which may be useful in monitoring more
specifically and sensitively the pathophysiological process of OA
and may provide a more sensitive prognosis of the patient.
The main objective of this study was to assess the relationship
of markers that reflect the process of inflammation, cartilage,
bone, and synovium tissue turnover in subjects with radiographic
signs of osteoarthritis (ROA) with symptomatic OA at multiple
sites (the GARP study) in order to generate hypothesis on the
different joint site specific pathophysiological processes that may
be reflected by these biochemical markers.
Methods: Markers that reflect the process of inflammation, car-
tilage, bone, and synovium tissue turnover were measured in
urine or serum. Urinary CTX-II (UCTX-II) and type IIA pro-
collagen amino terminal propeptide (PIIANP), serum cartilage
oligomeric matrix protein (COMP) were measured to represent
cartilage turnover. For bone, serum Osteocalcin (OC), and uri-
nary C-telopeptide of type I collagen (UCTX-I) were assessed, for
synovium urinary glucosyl-galactosyl pyridinoline (Glc-Gal-PYD)
and for inflammation serum high sensitive C-reactive Protein
(HsCRP) were measured. ROA was assessed in the knees,
hips, hands, vertebral facet joints and spinal disc degeneration
(DD) by the Kellgren and Lawrence score. A proportionate score
was made for each joint location based on the number of joints
with ROA. Principal component and linear mixed model analysis
was used in order to analyze the data.
Results: High familial aggregation was observed for S-COMP
(70%) and PIIANP (62%), whereas, moderate for UCTX-I (54%)
and Glc-Gal-PYD (51%). In our multivariate principal component
analyses we found 3 different clusters that may reflect different
pathophysiological processes of OA. The first component ap-
peared to be reflected by structural markers of cartilage and
bone turnover and associated especially in subjects with hip and
hand ROA. The second component was reflected by markers
of inflammation and was associated to subjects with knee ROA,
high WOMAC scores and BMI. In the third component markers
of cartilage turnover clustered together which was associated to
ROA at hands, spine and with increasing age.
Conclusions: Using a large well-characterized study in which
we evaluated most of the available molecular markers for bone,
synovial, and cartilage metabolism we were able to observe three
components that may reflect different molecular mechanisms;
bone turnover, inflammation and synovial degradation. Our data
suggested that these components may contribute differently to
ROA at different joint site.
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Purpose: Background: Cartilage matrix loss including type II
collagen is one of the hallmarks of osteoarthritis (OA). Type
II collagen degradation can be monitored by measuring the
fragments HELIX-II and CTX-II which originate from the triple
helical and C-telopeptide regions of the molecule, respectively.
Clinical studies have shown that urinary HELIX-II and CTX-II are
independently of each other associated with disease progression
in OA, suggesting that they may reflect in part different enzymatic
pathways of cartilage degradation.
Objective: To investigate the relative contribution of endogenous
MMPs and cysteine proteases- the two major classes of enzyme
believed to play a role in cartilage degradation in OA- on the re-
lease of HELIX-II and CTX-II from unstimulated human cartilage
explants in vitro
Methods: Full-depth cartilage from patients with OA undergoing
knee replacement were immediately deep frozen at -70°C to
preserve endogenous enzyme activity until assay. Sections were
then cut from frozen biopsies (200 μm thick), washed twice with
PBS and then incubated for 24, 48 or 96 hrs, at 37°C and gentle
agitation in buffers, which allowed activity of cysteine proteases
(ph 5.5+ cysteine) or of MMPs (pH 7.5+ APMA, an activator of
latent MMPs). In the same experiments, the activity of cysteine
proteases was inhibited by the non-selective inhibitor E-64 and
that of MMPs by GM6001. After incubation, the supernatant was
isolated, centrifuged (10 000 rpm), and the supernatant was kept
